pioglitazone has been researched along with Carcinoma in Situ in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keith, RL | 1 |
| Blatchford, PJ | 1 |
| Merrick, DT | 1 |
| Bunn, PA | 1 |
| Bagwell, B | 1 |
| Dwyer-Nield, LD | 1 |
| Jackson, MK | 1 |
| Geraci, MW | 1 |
| Miller, YE | 1 |
1 trial available for pioglitazone and Carcinoma in Situ
| Article | Year |
|---|---|
A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High-Risk Current and Former Smokers.
Topics: Aged; Biopsy; Bronchopulmonary Dysplasia; Bronchoscopy; Carcinoma in Situ; Chemoprevention; Double-B | 2019 |